Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1 Therapy in Patients with Relapsed or Refractory cHL
Data Show KEYTRUDA Monotherapy Significantly Reduced the Risk of Disease Progression or Death by 35% Compared with BV
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-204, a Phase 3 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In this pivotal study, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the dual primary endpoints.
Media:
Pamela Eisele
(267) 305-3558
Justine Moore
(908) 740-6449
Investors:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
